Hepatic dysfunction in childhood dengue infection

B Mohan1, A K Patwari, V K Anand

  • 1Department of Pediatrics, Lady Hardinge Medical College, New Delhi, India.

Insights

Childhood dengue infection (DI) can cause temporary liver function abnormalities, particularly in severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) cases, with or without hepatomegaly.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Hepatology

Background:

  • Dengue infection (DI) is a significant pediatric health concern.
  • Hepatic involvement is a common complication in childhood DI.
  • Understanding the pattern of liver function derangement is crucial for patient management.

Purpose of the Study:

  • To prospectively evaluate hepatic functions in children with DI during the acute phase.
  • To compare liver enzyme levels across different dengue severity classifications (DF, DHF, DSS).
  • To assess the impact of hepatomegaly on liver function tests in pediatric DI.

Main Methods:

  • Prospective study of 61 children (2 months-12 years) with DI.
  • Categorization into dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS).
  • Monitoring of liver function tests including AST, ALT, AP, and bilirubin levels during acute illness and hospitalization.

Main Results:

  • Elevated AST, ALT, and AP levels were observed in 80-87% of children on admission, irrespective of hepatomegaly.
  • Increased proportion and significantly higher mean levels of liver enzymes and bilirubin were noted in the second week of hospitalization (p < 0.05).
  • DHF and DSS cases exhibited significantly higher mean AST, ALT, and AP levels compared to DF (p < 0.05).

Conclusions:

  • Childhood dengue infection leads to transient liver function derangements.
  • The severity of liver involvement correlates with dengue severity, being more pronounced in DHF and DSS.
  • Liver function abnormalities in DI can occur with or without clinical hepatomegaly.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...